T Cell News and Research

Latest T Cell News and Research

Positive outcomes from imatinib trial in both older and younger patients with CML

While the median age at diagnosis for chronic myeloid leukemia is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.

31 Mar 2011

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

31 Mar 2011

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

Top-line results from Biomoda's CyPath pilot study against lung cancer

Cancer diagnostics company Biomoda, Inc. today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath's ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

Researchers identify drug candidate that can treat prostate cancer

The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.

31 Mar 2011

Regular CT scans can cause secondary malignancies in older men with testicular cancer

UC Davis cancer researchers have found that older men with early-stage testicular cancer who opt for surveillance with regular CT scans over lymph node removal are at greater risk for secondary cancers.

31 Mar 2011

3D experiments reveal MSCs have potential to produce different cell types

A type of adult stem cell is now proving itself more versatile for research and therapies thanks to revolutionary 3D experiments. These cells have already shown great promise for repairing damaged bone and cartilage but until now have been fairly limited in the types of cells they can form in the laboratory.

31 Mar 2011

Mucus may play a key role in penetration of hydrophobic substances into cells

Are our bodies vulnerable to some pollutants whose lack of solubility in water, or "hydrophobicity," has always been thought to protect us from them? New Tel Aviv University research has discovered that this is indeed the case.

31 Mar 2011

Study provides insight into kidney cancer

Researchers at UT Southwestern Medical Center have discovered genetic pathways to starve selectively kidney cancer cells.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

Report examines how new technologies can aid in humanitarian response to disasters

A new report examines how new technologies, including digital mapping, can influence emergency relief work and says technology will not be able to fully transform humanitarian aid without "better coordination and communication between digital volunteers and veteran agencies in the relief field, like the United Nations and the Red Cross," the New York Times reports.

30 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

TAP announces new corporate identity

The Automation Partnership, a leading supplier of innovative automation for life science applications today announced that the company will now be known as TAP Biosystems.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have employed a strategy using a mouse model to target important mechanisms inside the most challenging breast cancer cells. Earlier studies at Cedars-Sinai found a similar approach effective in attacking malignant brain tumor targets.

30 Mar 2011